By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Foundation Medicine's today said that its genomic tests will be used by biopharmaceutical company Celgene for clinical trials of its anti-cancer drug candidates.

Foundation's test, which is under development, will be used to hasten faster recruitment of target patient populations and for broad genetic characterization of trial enrollees in order to identify patients most likely to respond to Celgene's drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.